NAFLD
-
Gilead NASH drug dead in the water as second Phase III trial fails
An analyst wrote that with selonsertib’s failures in fourth- and now third-stage fibrosis, the drug will have no place in NASH treatment. Gilead has entered partnerships focused on other compounds for the fatty liver disease.
-
Genfit makes $135M debut on Nasdaq
The French company, developing a drug to treat nonalcoholic steatohepatitis, or NASH, announced the pricing of its shares at $20.32 apiece.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Genfit, developing drugs for NASH, to trade on Nasdaq
The company, one of several developing drugs for the growing fatty liver disease, said in an SEC filing that it would sell its shares at $26.33 apiece.
-
Intercept could score first NASH drug approval on positive Phase III data
Shares of the New York-based company jumped nearly 20 percent Tuesday on news that the REGENERATE study of obeticholic acid showed strong improvement in NASH-related liver fibrosis.
-
Chinese-American startup Terns Pharmaceuticals raises $80M for NASH, cancer drugs
The company joins a growing wave of firms developing drugs for the disease, which has no approved treatments. It expects to enter two drugs into the clinic next year.
-
Novartis, Pfizer partner to develop drugs for NASH
The companies will run clinical trials combining Novartis’ tropifexor with any one of several Pfizer drugs under development for the disease, which lacks approved treatments.
-
OrbiMed launches 89Bio with $60M Series A round to develop Teva’s NASH drug
The new company is headquartered in San Francisco, with R&D in Israel and has launched a Phase I study of BIO89-100, formerly TEV-47948.
-
Ambys Medicines garners $140 million to develop chronic liver disease treatments
The company secured $60 million in a Series A round from Third Rock and Takeda, plus a partnership with Takeda.
-
Three major variables that could derail the dash to NASH
From clinical trial saturation to a suspiciously strong placebo effect: Here are some of the major challenges facing biopharma companies in pursuit of the first FDA-approved therapy for non-alcoholic steatohepatitis (NASH).
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
In dash to NASH, Immuron targets the gut not the liver
Cookies and milk or cookies and colostrum? Immuron is targeting inflammatory bacteria in the gut with an engineered colostrum formulation, designed to prevent the liver damage that leads to NASH.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
